Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

6.2%

45 terminated/withdrawn out of 729 trials

Success Rate

89.1%

+2.6% vs industry average

Late-Stage Pipeline

20%

143 trials in Phase 3/4

Results Transparency

11%

40 of 367 completed trials have results

Key Signals

70 recruiting40 with results34 terminated11 withdrawn

Enrollment Performance

Analytics

N/A

177(32.4%)

Phase 2

169(31.0%)

Phase 4

85(15.6%)

Phase 3

58(10.6%)

Phase 1

56(10.3%)

Early Phase 1

1(0.2%)

546Total

N/A(177)

Phase 2(169)

Phase 4(85)

Phase 3(58)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (729)

Showing 20 of 729 trials

NCT07641283Not ApplicableNot Yet Recruiting

Naltrexone for Nonsuicidal Self-Injury

Role: collaborator

NCT06937463Not ApplicableCompleted

Use of an Off-the-Shelf Exergame as an In-Bed Gamified Rehabilitation Intervention for Severely Deconditioned Inpatients: A Feasibility Study

Role: lead

NCT07621458Recruiting

Study on Cutoff Revision Effects and Evaluation of NNT in Primary Aldosteronism

Role: collaborator

NCT06914011Phase 3Not Yet Recruiting

Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma

Role: lead

NCT07043855Not ApplicableEnrolling By Invitation

Duration of Perioperative Antibiotics in Pancreatoduodenectomy

Role: lead

NCT07495579Phase 2Not Yet Recruiting

Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE)

Role: lead

NCT07606430Not ApplicableNot Yet Recruiting

Comparison of a Short Modified Metal Stent Versus Plastic Stent as a Bridge to Surgery in Pancreatic Cancer With Malignant Biliary Obstruction

Role: collaborator

NCT04264975Not ApplicableRecruiting

Utilization of Microbiome as Biomarkers and Therapeutics in Immuno-Oncology

Role: lead

NCT04494009Phase 2Active Not Recruiting

PD-1 Inhibitor INCMGA00012 as Consolidation Therapy After Definitive Concurrent Chemoradiotherapy

Role: lead

NCT04196465Phase 2Active Not Recruiting

Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers

Role: lead

NCT07497867Recruiting

Long-term Prospective Study of Korean CADASIL Patients

Role: collaborator

NCT07556770Not Yet Recruiting

Sonographic Safety Margins of Subclavian Vein: Effect of View and Arm Position

Role: lead

NCT05148052Not ApplicableCompleted

Effect of Upper Extremity Rehabilitation Using Immersive Virtual Reality in Chronic Stroke Patients.

Role: collaborator

NCT06330038Phase 4Recruiting

Anesthesia and Non-small Cell Lung Cancer Recurrence

Role: collaborator

NCT06849765Not ApplicableCompleted

Feasibility and Safety of Digital Rehab Platform for Bedridden Patients

Role: lead

NCT07530393Not Yet Recruiting

Blood Viscosity and Outcomes After Elective Craniotomy

Role: lead

NCT07089589Completed

Preoperative Statin Use and Major Adverse Cardiovascular Events in Liver Transplant Recipients

Role: lead

NCT05418556Phase 4Recruiting

Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent

Role: lead

NCT05801432Recruiting

A Study to Evaluate Coronary Atherosclerosis in Patients With Diabetes Mellitus

Role: lead

NCT05805280Not ApplicableCompleted

IntravasCular Imaging-Guided Versus AngiogRaphy-GUided Drug-Eluting Stent Implantation for Fermoropopliteal Artery Disease

Role: lead